Skin rashes and stomatitis due to parenteral treatment of rheumatoid arthritis with sodium aurothiomalate.
AUTOR(ES)
Svensson, A
RESUMO
In a prospective study of 45 patients with rheumatoid arthritis mucocutaneous symptoms and signs were evaluated before and during treatment with intramuscular sodium aurothiomalate (Myocrisin). The work, performed in close collaboration between dermatology and rheumatology departments, showed that there was no significant increase in mucocutaneous side effects in patients with pre-existing mucocutaneous disease. It is concluded that pre-existing dermatitis is not a contraindication for treatment with gold salts and that a previous mucocutaneous reaction to gold salts is not an absolute contraindication for a new trial of chrysotherapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1004653Documentos Relacionados
- Changes in immune function in patients with rheumatoid arthritis following treatment with sodium aurothiomalate.
- Serum gold determinations in patients with rheumatoid arthritis receiving sodium aurothiomalate.
- Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate.
- Gold levels produced by treatment with auranofin and sodium aurothiomalate.
- Combined suppressive drug treatment in severe refractory rheumatoid disease: an analysis of the relative effects of parenteral methylprednisolone, cyclophosphamide, and sodium aurothiomalate.
